Exact Mass: 487.1640656

Exact Mass Matches: 487.1640656

Found 318 metabolites which its exact mass value is equals to given mass value 487.1640656, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Luciferyl sulfate

Renilla luciferyl sulfate

C26H21N3O5S (487.12018560000007)

YC 170

3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethyl-5-((phenylamino)carbonyl)-, 2-(2-pyridinyl)ethyl ester

C28H26ClN3O3 (487.1662596000001)

Myxothiazol

Myxothiazol A

C25H33N3O3S2 (487.1963228)

A 2,4-bi-1,3-thiazole substituted at the 4-position with a (1E,3S,4R,5E)-7-amino-3,5-dimethoxy-4-methyl-7-oxohepta-1,5-dien-1-yl] group and at the 2-position with a (2S,3E,5E)-7-methylocta-3,5-dien-2-yl group. It is an inhibitor of coenzyme Q - cytochrome c reductase. D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D004791 - Enzyme Inhibitors

Flucetosulfuron

C18H22FN5O8S (487.1173064)

Dasatinib

N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

C22H26ClN7O2S (487.1557126000001)

Dasatinib is only found in individuals that have used or taken this drug. It is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR&beta. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Pyranocyanin B

7-(3,4-dihydroxyphenyl)-11-hydroxy-3-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2λ⁴,8-dioxatricyclo[7.3.1.0⁵,¹³]trideca-1,3,5(13),6,9,11-hexaen-2-ylium

C24H23O11 (487.1240308)

Pyranocyanin B is found in fruits. Pyranocyanin B is a constituent of the seeds of Ribes nigrum (blackcurrant) Constituent of the seeds of Ribes nigrum (blackcurrant). Pyranocyanin B is found in fruits.

2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide

C25H21F4N3O3 (487.15189640000006)

(2S)-3-[[2-[(5R)-3-(4-Carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]-2-[(3-methylphenyl)sulfonylamino]propanoic acid

(2S)-3-[[2-[(5R)-3-(4-Carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]-2-[(3-methylphenyl)sulphonylamino]propanoic acid

C22H25N5O6S (487.152547)

Methylsulfonyl 4-[(2-carbamimidoyl-3,4-dihydro-1H-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylate

Methanesulphonyl 4-{[(2-carbamimidoyl-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy]methyl}-1-(pyridin-4-yl)piperidine-4-carboxylic acid

C23H29N5O5S (487.18893040000006)

Malvidin 3-alpha-L-galactoside

2-(3-ethenyl-5-methoxy-4-methylphenyl)-5,7-dihydroxy-3-{[(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1λ⁴-chromen-1-ylium

C25H27O10 (487.1604142)

Malvidin 3-alpha-l-galactoside is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Malvidin 3-alpha-l-galactoside can be found in highbush blueberry, which makes malvidin 3-alpha-l-galactoside a potential biomarker for the consumption of this food product.

Pemigatinib

11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-[(morpholin-4-yl)methyl]-5,7,11,13-tetraazatricyclo[7.4.0.0^{2,6}]trideca-1,3,6,8-tetraen-12-one

C24H27F2N5O4 (487.2031006000001)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EN - Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor

Sarecycline

(4S,4AS,5ar,12as)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-{[methoxy(methyl)amino]methyl}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboximidate

C24H29N3O8 (487.1954554)

J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01A - Tetracyclines > J01AA - Tetracyclines C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic D003879 - Dermatologic Agents

A spiruchostatin with molecular formula C21H33N3O6S2 originally isolated from a Pseudomonas culture broth. D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors

Folinic acid

C21H25N7O7 (487.181538)

11,11-dechloro-4-demethylrebeccamycin|12-[beta-D-glucopyranosyl]-6,7,12,13-tetrahydroindolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione

C26H21N3O7 (487.1379436)

Pancratiside

C20H25NO13 (487.132584)

usimine A

C24H25NO10 (487.147839)

4-hydroxy-3-methoxyphenylacetonitrile 4-O-beta-D-glucopyranosyl(1->6)-beta-D-glucopyranoside|adenophoraside B

C21H29NO12 (487.16896740000004)

C18H33NO14

C18H33NO14 (487.1900958)

Cys Ala Pro Pro Thr

C20H33N5O7S (487.21005880000007)

Dasatinib (BMS-354825)

C22H26ClN7O2S (487.1557126000001)

Ala Asp Pro Trp

(3S)-3-[(2S)-2-aminopropanamido]-4-[(2S)-2-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}pyrrolidin-1-yl]-4-oxobutanoic acid

C23H29N5O7 (487.2066884)

Ala Asp Trp Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carboxypropanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carboxylic acid

C23H29N5O7 (487.2066884)

Ala Pro Asp Trp

(3S)-3-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C23H29N5O7 (487.2066884)

Ala Pro Trp Asp

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanamido]butanedioic acid

C23H29N5O7 (487.2066884)

Ala Trp Asp Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-indol-3-yl)propanamido]-3-carboxypropanoyl]pyrrolidine-2-carboxylic acid

C23H29N5O7 (487.2066884)

Ala Trp Pro Asp

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}butanedioic acid

C23H29N5O7 (487.2066884)

Cys Asp His Asn

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-1-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)

Cys Asp Asn His

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-2-carbamoyl-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)

Cys His Asp Asn

(3S)-3-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)

Cys His Asn Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]butanedioic acid

C17H25N7O8S (487.148525)

Cys His Gln Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanamido]-3-hydroxybutanoic acid